XTNT - Xtant Medical GAAP EPS of -$0.02 in-line revenue of $20.23M beats by $0.73M
2023-08-01 07:05:34 ET
- Xtant Medical press release ( NYSE: XTNT ): Q2 GAAP EPS of -$0.02 in-line.
- Revenue of $20.23M (+32.4% Y/Y) beats by $0.73M .
- Xtant Medical raises its expectation for full year 2023 revenue to $75 million to $77 million, up from the Company’s prior guidance of $73 million to $75 million. The revised guidance range represents annual revenue growth of approximately 29% to 33% compared to full year 2022 revenue, and excludes any potential contributions from the Surgalign transaction, if and when that transaction closes.
For further details see:
Xtant Medical GAAP EPS of -$0.02 in-line, revenue of $20.23M beats by $0.73M